Your browser doesn't support javascript.
loading
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri, Carlo; Macpherson, Iain Rj; Yan, Kelvin; Ades, Felipe; Riddle, Pippa; Ahmed, Riz; Owadally, Waheeda; Stanley, Barbara; Shah, Deep; Gojis, Ondrej; Januszewski, Adam; Lewanski, Conrad; Asher, Rebecca; Lythgoe, Daniel; de Azambuja, Evandro; Beresford, Mark; Howell, Sacha J.
Afiliación
  • Palmieri C; Academic Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
  • Macpherson IR; Liverpool and Merseyside Academic Breast Unit, The Linda McCartney Centre, Royal Liverpool University Hospital, Liverpool, UK.
  • Yan K; The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, UK.
  • Ades F; Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Riddle P; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Ahmed R; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Owadally W; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Stanley B; Department of Clinical Oncology, West Middlesex University Hospital, London, UK.
  • Shah D; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Gojis O; Department of Clinical Oncology, West Middlesex University Hospital, London, UK.
  • Januszewski A; Department of Clinical Oncology, The Royal United Hospital, Combe Park, Bath, UK.
  • Lewanski C; Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Asher R; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Lythgoe D; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • de Azambuja E; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Beresford M; Ealing Hospital NHS Trust, Middlesex, UK.
  • Howell SJ; Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, UK.
Oncotarget ; 7(11): 13209-20, 2016 Mar 15.
Article en En | MEDLINE | ID: mdl-26334099
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adyuvante / Terapia Neoadyuvante / Trastuzumab Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adyuvante / Terapia Neoadyuvante / Trastuzumab Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Oncotarget Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido